NEW DELHI: A committee of experts at the apex drug regulator has deferred its decision on Serum Institute of India Pvt Ltd’s covid-19 vaccine trial, and has asked the company to amend its protocol for the phase II and III clinical trial of the University of Oxford’s vaccine candidate.“After detailed deliberation the committee recommended for amendment to the protocol… Accordingly, the firm should submit revised protocol for evaluation of the committee," as per minutes of Tuesday’s meeting of the subject expert committee (SEC) for covid-19 related proposal in the Central Drugs Standards Control Organization, a copy of which has been seen by Mint.An email sent to Serum Institute of India on this development remained unanswered at the time of.